Tenofovir disoproxil

This classification denotes a reverse transcriptase inhibitor and purine antagonist C19H30N5O10P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F4YU4LON7I, chemically known as 2,4,6,8-tetraoxa-5-phosphanonanedioic acid, 5-(((1r)-2-(6-amino-9h-purin-9-yl)-1-methylethoxy)methyl)-, 1,9-bis(1-methylethyl) ester, 5-oxide, but more generally known as tenofovir disoproxil, which bears US NIH Compound Identifier 5481350. European Medicines Agency schedules Tenofovir disoproxil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20643. Most nations, for tariff and trade purposes, schedule tenofovir disoproxil under HS 29335995 and SITC 51576. World Health Organization schedules tenofovir disoproxil in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, TENOFOVIR DISOPROXIL remains US FDA's Preferred Term for this commodity. SMILES: C[C@H](CN1CNC2C1NCNC2N)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C.